Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Second-line FOLFIRINOX in unresectable cholangiocarcinoma
NL-OMON42542Phase 2Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Dec 2015
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin, irinotecan, folinic acid and fluorouracil in cholangiocarcinoma (CCA), biliary cancer and gallbladder cancer, sponsored by Amsterdam University Medical Center. Primary endpoints: Toxicity and Response rate. Started Dec 2015; status: active, not recruiting.
02
Drugs
oxaliplatinirinotecanfolinic acidfluorouracil
03
Conditions
cholangiocarcinoma (CCA)biliary cancergallbladder cancer
Beyond the preview
Go deeper on NL-OMON42542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42542.